HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Ofloxacin resistance in multibacillary new leprosy cases from Purulia, West Bengal: a threat to effective secondary line treatment for rifampicin-resistant leprosy cases.

AbstractOBJECTIVES:
Purulia is one of the high-endemic districts for leprosy in West Bengal (the eastern part of India). The annual new case detection rate (ANCDR) of leprosy in West Bengal is 6.04/100000 (DGHS 2019-20). Our earlier report provided evidence of secondary drug resistance in relapse cases of leprosy. The aim of the current study was to observe primary drug resistance patterns for dapsone, rifampicin, and ofloxacin amongst new leprosy patients from Purulia, West Bengal in order to better understand the emergence of primary resistance to these drugs.
METHODS:
In the present study, slit-skin smear samples were collected from 145 newly diagnosed leprosy cases from The Leprosy Mission (TLM) Purulia hospital between 2017 and 2018. DNA was extracted from these samples and the Mycobacterium leprae genome was analyzed for genes associated with drug resistance by polymerase chain reaction (PCR), followed by Sanger sequencing. Wild-type strain (Thai-53) and mouse footpad-derived drug-resistant strain (Z-4) were used as reference strains.
RESULTS:
Of 145 cases, 25 cases showed mutations in genes associated with resistance to rifampicin, dapsone, and ofloxacin (as described by the World Health Organization, rpoB, folP, and gyrA, respectively) through Sanger sequencing. Of these 25 cases, 16 cases showed mutations in ofloxacin, two cases showed mutations in combinations of ofloxacin and rifampicin, four cases showed a mutation only in rifampicin, one case showed mutations in combinations of rifampicin and dapsone, and two cases showed mutations only in dapsone.
CONCLUSION:
Results from this study indicated the emergence of resistance to antileprosy drugs in new cases of leprosy. As ofloxacin is the alternate drug for the treatment of rifampicin-resistant cases, the emergence of new cases with resistance to ofloxacin indicates that ofloxacin-resistant M. leprae strains are actively circulating in this endemic region (i.e., Purulia, West Bengal), posing challenges for the effective treatment of rifampicin-resistant cases.
AuthorsMadhvi Ahuja, Itu Singh Dr, Mallika Lavania Dr, Vinay Kumar Pathak, Joydeepa Darlong Dr, Ravindra P Turankar Dr, S Hembrom Dr, Shoor Veer Singh Dr, Utpal Sengupta Dr
JournalJournal of global antimicrobial resistance (J Glob Antimicrob Resist) Vol. 30 Pg. 282-285 (09 2022) ISSN: 2213-7173 [Electronic] Netherlands
PMID35717020 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
CopyrightCopyright © 2022 The Authors. Published by Elsevier Ltd.. All rights reserved.
Chemical References
  • Leprostatic Agents
  • Dapsone
  • Ofloxacin
  • Rifampin
Topics
  • Animals
  • Dapsone (pharmacology, therapeutic use)
  • Drug Resistance, Bacterial (genetics)
  • Leprostatic Agents (pharmacology, therapeutic use)
  • Leprosy (drug therapy, epidemiology, microbiology)
  • Mice
  • Mycobacterium leprae (genetics)
  • Ofloxacin (pharmacology, therapeutic use)
  • Rifampin (pharmacology, therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: